Company intelligence / Profile preview

Qx Therapeutics Inc.

New Haven, Connecticut, United States

Ownership: Private
Development stage: Phase 2

Overview

Qx Therapeutics’ lead candidate, QXT-101, is a first-in-class MAP3K2/3 inhibitor for the treatment of acute lung injury and related conditions. The company has received FDA authorization to proceed with a Phase 2 clinical trial evaluating safety and efficacy of QXT-101 for prevention and treatment of primary graft dysfunction in lung transplant recipients. Preclinical studies have demonstrated proof-of-concept efficacy across multiple animal models of ALI and ARDS caused by various insults, including reperfusion injury[4].

Therapeutic areas: Pulmonology
Modalities: Small molecule inhibitors (MAP3K2/3 inhibitors)
Industry: Biotech

Drug pipeline

1 asset

QXT-101

Unknown

Beyond the preview

Go deeper on Qx Therapeutics Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Qx Therapeutics Inc..

Explore the full profile